Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $469.85 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 128.97 million
Earnings per share -0.108
Dividend per share N/A
Year To Date Return -2.39%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News

female nurse in scrubs
Healthcare Shares

Fundie names underappreciated ASX biotech share with ‘significant upside’

Why is this ASX biotech share a potential winner?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Share Gainers

The Neuren Pharmaceuticals (ASX:NEU) share price has soared 102% so far this month. Here’s why

The ASX biopharmaceutical company is having a stellar month.

Read more »

santa looks intently at his mobile phone with gloved finger raised and christmas tree in the background.
Share Gainers

3 ASX shares giving the gift of gains heading into Christmas

These companies are acting as the stocking stuffers for investor portfolios this year...

Read more »

three excited doctors with hands in the air
Healthcare Shares

Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results

Why are investors so excited about Neuren Pharmaceuticals today?

Read more »

Medical professionals cheering good news. pro medicus
Share Gainers

Here’s why the Neuren Pharmaceuticals (ASX:NEU) share price is up 11%

We take a look at what the pharmaceutical company announced today

Read more »

medical asx share price represented by doctor giving thumbs up
Share Market News

Why the Neuren (ASX:NEU) share price is moving higher today

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is treading higher today after announcing strong progress on its milestone targets.

Read more »

good news and bad for asx shares represented by same man pictured happy and then sad
Share Market News

The Neuren (ASX:NEU) share price is falling today despite positive news

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is climbing higher today. This comes after the company announced that it…

Read more »

laboratory workers looking disappointed
Share Fallers

Why this small cap ASX healthcare share is dropping lower today

The Neuren Pharmaceuticals Ltd (ASX:NEU) share price is dropping lower on Friday despite the release of a positive update...

Read more »

NEU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.

NEU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $3.68 $0.03 0.82% 179,850 $3.61 $3.82 $3.58
13 May 2022 $3.65 $0.10 2.82% 206,458 $3.57 $3.67 $3.47
12 May 2022 $3.55 $-0.19 -5.08% 196,941 $3.71 $3.73 $3.53
11 May 2022 $3.74 $0.04 1.08% 88,989 $3.70 $3.78 $3.67
10 May 2022 $3.70 $0.09 2.49% 154,533 $3.52 $3.71 $3.46
09 May 2022 $3.61 $-0.14 -3.73% 177,945 $3.70 $3.73 $3.56
06 May 2022 $3.75 $-0.05 -1.32% 77,265 $3.76 $3.76 $3.66
05 May 2022 $3.80 $0.10 2.70% 124,719 $3.70 $3.80 $3.69
04 May 2022 $3.70 $-0.10 -2.63% 51,528 $3.80 $3.82 $3.70
03 May 2022 $3.80 $0.05 1.33% 151,887 $3.72 $3.84 $3.72
02 May 2022 $3.75 $-0.08 -2.09% 160,396 $3.80 $3.85 $3.66
29 Apr 2022 $3.83 $0.03 0.79% 82,143 $3.81 $3.83 $3.75
28 Apr 2022 $3.80 $-0.06 -1.55% 109,913 $3.80 $3.86 $3.77
27 Apr 2022 $3.86 $0.01 0.26% 229,547 $3.80 $3.88 $3.77
26 Apr 2022 $3.85 $-0.09 -2.28% 67,254 $3.82 $3.92 $3.80
22 Apr 2022 $3.94 $0.01 0.25% 101,970 $3.95 $3.97 $3.88
21 Apr 2022 $3.93 $0.03 0.77% 77,008 $3.95 $3.99 $3.86
20 Apr 2022 $3.90 $0.02 0.52% 95,041 $3.85 $3.91 $3.83

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Oct 2021 Dianne Angus Buy 30 $59,316
On-market trade.
08 Oct 2021 Jonathan (Jon) Pilcher Buy 7 $15,000
Participation in share purchase plan.
08 Oct 2021 Jenny Harry Buy 9 $20,000
Participation in share purchase plan.
08 Oct 2021 Patrick Davies Buy 14 $30,000
Participation in share purchase plan.
24 Jun 2021 Patrick Davies Buy 43 $61,172
On-market trade.
15 Jun 2021 Jonathan (Jon) Pilcher Buy 19 $25,000
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Trevor D Scott Non-Executive Director Mar 2002
Dr Scott is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a range of industries. Trevor serves on corporate boards and is also serving as chairman at some corporates.
Ms Dianne Margaret Angus Non-Executive Director Jul 2018
Ms Angus has worked as a senior executive and non-executive director within the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created range of global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory & Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. She has forged partnerships with key medical opinion leaders to create clinical research programs and driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over fifteen years experience in listed company, she has expertise in business development, capital raising, investor relations, regulatory affairs and intellectual property, together with corporate governance and compliance capabilities.
Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
Mr Pilcher has financial and capital markets knowledge with a science background, Jon has corporate and R&D executive experience in international listed pharmaceutical companies.
Dr Jenny Lee Harry Non-Executive Director Jul 2018
Dr Harry has 20 years experience in executive management of companies in the biotechnology and biopharmaceutical sectors. As CEO and Managing Director of Tyrian Diagnostics, Jenny transformed the company from an R&D business to a diagnostics company and oversaw development of the company's first products through to commercialisation and early revenue generation. She is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Jenny is currently a Non-Executive Director on the boards of Ondek Pty Ltd.
Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. He is a director on other corporate boards and provides advice to a range of healthcare businesses and investors.
Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
Lauren Frazer Chief Financial OfficerCompany Secretary
Larry Glass Chief Science Officer
James Shaw Vice President Clinical & Regulatory Operations
Nancy Jones Vice President Clinical Development
Clive Blower Vice President Product Development

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited Gsco Eca 14,321,650 12.50%
Cameron Richard Pty Ltd 5,865,240 5.12%
Citicorp Nominees Pty Limited 4,811,785 4.20%
Stuart Andrew Pty Ltd 2,951,929 2.58%
National Nominees Limited 2,951,041 2.57%
HSBC Custody Nominees (Australia) Limited 2,948,200 2.57%
Linwierik Super Pty Ltd 2,642,143 2.31%
Brispot Nominees Pty Ltd 2,482,733 2.17%
Essex Castle Limited 2,369,251 2.07%
Smithley Super Pty Ltd 2,140,000 1.87%
Hobson Wealth Custodians Ltd 1,580,145 1.38%
MXB Investments LLC 1,330,000 1.16%
CS Fourth Nominees Pty Limited 1,234,490 1.08%
UBS Nominees Pty Ltd 1,207,722 1.05%
First Colbyco Pty Ltd 1,028,520 0.90%
Dr Trevor Scott 1,000,000 0.87%
Dr Robin Lance Congreve 991,637 0.87%
Dr Richard Spencer Treagus 903,500 0.79%
BNP Paribas Nominees Pty Ltd Six Sis Ltd 735,859 0.64%
Namarong Investments Pty Ltd 555,556 0.48%